Clinical Trials Directory

Trials / Sponsors / Repros Therapeutics Inc.

Repros Therapeutics Inc.

Industry · 58 registered clinical trials.

StatusTrialPhaseStarted
TerminatedAn Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopa
Uterine Fibroids
Phase 22016-07-26
CompletedA Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition
Acquired Hypogonadotropic Hypogonadism, Obesity
Phase 22016-01-11
CompletedA Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 1
Uterine Fibroids
Phase 22015-03-16
CompletedSafety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fi
Uterine Fibroids
Phase 22015-02-12
CompletedAn Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolab
Secondary Hypogonadism
Phase 12014-12-01
CompletedAn Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal
Pharmacokinetics
Phase 12014-08-01
CompletedStudy to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal
Normal Volunteers
Phase 12014-06-01
CompletedAssessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
Drug-drug Interaction
Phase 12014-05-01
CompletedComparison of Two Formulations of Proellex for Oral Administration
Healthy
Phase 12014-05-01
CompletedA Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects
Healthy
Phase 12014-04-01
CompletedA Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotr
Secondary Hypogonadism
Phase 32014-01-01
CompletedA Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotr
Secondary Hypogonadism
Phase 32014-01-01
CompletedComparison of Two Formulations of Androxal
Bioequivalence
Phase 12013-12-31
WithdrawnOpen-Label Extension Study to ZPE-202
Endometriosis
Phase 22013-12-01
CompletedComparison of Two Formulations of Proellex for Vaginal Administration
Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Phase 12013-10-01
CompletedA Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
Pharmacokinetics, Tolerability
Phase 12013-10-01
CompletedEvaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
Secondary Hypogonadism
Phase 12013-08-01
CompletedEvaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Secondary Hypogonadism
Phase 12013-08-01
CompletedSafety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirme
Endometriosis
Phase 22013-05-02
CompletedPhase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32012-11-01
CompletedAn Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32012-11-01
CompletedExtension of Study ZPV-200
Uterine Fibroids
Phase 22012-09-01
CompletedAssessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism
Effect of Treatment on Bone Mineral Density
Phase 32012-09-01
CompletedSafety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatm
Uterine Fibroids
Phase 22012-09-01
CompletedPhase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32012-08-01
CompletedSafety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32012-05-01
CompletedEvaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine
Uterine Fibroids
Phase 22012-02-01
CompletedA One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-
Hypogonadism, Low Testosterone
Phase 22011-07-01
CompletedThe Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testost
Secondary Hypogonadism
Phase 22011-06-01
CompletedNormalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 22011-01-01
CompletedStudy to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
Type 2 Diabetes Mellitus, Secondary Hypogonadism
Phase 22010-10-01
CompletedDetermination of the Lowest, Safe and Effective Dose of Proellex
Amenorrhea
Phase 1 / Phase 22010-08-01
TerminatedSafety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Uterine Fibroids
Phase 32009-04-01
CompletedInvestigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Femal
ABSORPTION, METABOLISM, EXCRETION
Phase 12009-04-01
TerminatedStudy Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
Endometriosis
Phase 22009-02-28
TerminatedEvaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Uterine Fibroids
Phase 32009-02-01
TerminatedStudy to Evaluate Menses Induction in Women Administered Proellex
Amenorrhea
Phase 12009-02-01
TerminatedEvaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Fema
Renal Impairment
Phase 1 / Phase 22008-10-01
TerminatedSafety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Uterine Fibroids, Anemia
Phase 32008-10-01
TerminatedMulticenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Uterine Fibroids
Phase 32008-10-01
CompletedEvaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
Impaired Liver Function
Phase 12008-10-01
CompletedCrossover Study of the Safety and PK Properties of Proellex®
Pharmacokinetics
Phase 12008-08-11
TerminatedEvaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fib
Uterine Fibroids
Phase 32008-08-01
CompletedOpen-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjec
Drug Interactions
Phase 12008-07-01
TerminatedAn Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003
Uterine Fibroids
Phase 22008-06-01
TerminatedSafety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
Uterine Fibroids, Anemia
Phase 32008-06-01
CompletedTo Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
Secondary Hypogonadism
Phase 22008-06-01
TerminatedPharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibro
Uterine Fibroids
Phase 22008-05-01
CompletedProellex® Pharmacokinetic Bridging Study II
Healthy
Phase 12008-02-29
CompletedA Safety and Pharmacokinetic Study of Proellex®
Healthy
Phase 12008-02-01
TerminatedSafety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endome
Endometriosis
Phase 22007-11-01
CompletedProellex Pharmacokinetics Bridging Study
Healthy
Phase 12007-06-01
CompletedExtension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Uterine Fibroids
Phase 22006-09-07
CompletedStudy to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32006-03-01
CompletedStudy of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Uterine Fibroids
Phase 22006-03-01
CompletedStudy to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
Secondary Hypogonadism
Phase 32006-03-01
CompletedA Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
Uterine Leiomyomata
Phase 1 / Phase 22004-07-01
WithdrawnSafety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms
Uterine Fibroids
Phase 3